[May 26, 2016]

Global Peripheral Neuropathic Pain Therapeutics Pipeline Report 2016 - 10 Companies & Drug Profiles - Research and Markets

Research and Markets has announced the addition of the "Peripheral Neuropathic Pain - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Peripheral Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathic Pain and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-inclass products.

Key Topics Covered:

1. Introduction
2. Peripheral Neuropathic Pain Overview
3. Therapeutics Development
4. Pipeline Products for Peripheral Neuropathic Pain - Overview
5. Pipeline Products for Peripheral Neuropathic Pain - Comparative Analysis
6. Peripheral Neuropathic Pain - Therapeutics under Development by Companies
7. Peripheral Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes
8. Peripheral Neuropathic Pain Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Peripheral Neuropathic Pain - Products under Development by Companies
13. Peripheral Neuropathic Pain - Products under Investigation by Universities/Institutes
14. Peripheral Neuropathic Pain - Companies Involved in Therapeutics Development

• Achelios Therapeutics, Inc.
• AnaBios Corporation
• Chromocell Corporation
• Eli Lilly and Company
• GW Pharmaceuticals Plc
• Nektar Therapeutics
• Phosphagenics Limited
• Spherium Biomed S.L.
• Sunovion Pharmaceuticals Inc.
• Zynerba Pharmaceuticals, Inc.

For more information visit http://www.researchandmarkets.com/research/bfhjwd/peripheral

View source version on businesswire.com: http://www.businesswire.com/news/home/20160526005792/en/

[ Back To TMCnet.com's Homepage ]